<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Conner Merritt | Activity</title>
	<link>https://www.catswannabecats.com/members/netbait00/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/netbait00/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Conner Merritt.</description>
	<lastBuildDate>Mon, 29 Jun 2026 10:35:48 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">2f8b46fbef5773cd7d81f444e66908b2</guid>
				<title>Conner Merritt posted an update: There were significant differences among the three groups in [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23712/</link>
				<pubDate>Sun, 08 Jun 2025 10:22:37 -0400</pubDate>

									<content:encoded><![CDATA[<p>There were significant differences among the three groups in symptoms, largest diameter of the gestational sac, presence of fetal heartbeat, myometrial thickness, type of cesarean scar pregnancy, blood loss, length of hospital stay, and expense. The rates of complications and success were 8.2% and 93.6%, respectively. Thirty-seven women conceived&hellip;<span class="activity-read-more" id="activity-read-more-23712"><a href="https://www.catswannabecats.com/activity/p/23712/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">977067d565139c27eec7b3806608a9ae</guid>
				<title>Conner Merritt posted an update: Specifically, the use of venetoclax in targeting BCL2 has [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/10050/</link>
				<pubDate>Sat, 31 May 2025 23:42:45 -0400</pubDate>

									<content:encoded><![CDATA[<p>Specifically, the use of venetoclax in targeting BCL2 has been promising in BPDCN treatment. This review will focus on the underlying diagnostic markers of BPDCN which have led to novel targeted treatment strategies, as well as future directions in therapy we can expect in coming years.</p>
<p> Personal protective equipment (PPE) compliance is&hellip;<span class="activity-read-more" id="activity-read-more-10050"><a href="https://www.catswannabecats.com/activity/p/10050/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7b57086d01810ba99a9c939d6d9c1ead</guid>
				<title>Conner Merritt became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/7943/</link>
				<pubDate>Sat, 31 May 2025 20:18:34 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>